{"id":"https://openalex.org/W3207324364","doi":"https://doi.org/10.1016/j.jns.2021.118787","title":"Safety of eculizumab in NMOSD and MG: Analysis of the phase 3 studies prevent and regain, and their extensions","display_name":"Safety of eculizumab in NMOSD and MG: Analysis of the phase 3 studies prevent and regain, and their extensions","publication_year":2021,"publication_date":"2021-10-01","ids":{"openalex":"https://openalex.org/W3207324364","doi":"https://doi.org/10.1016/j.jns.2021.118787","mag":"3207324364"},"language":"en","primary_location":{"id":"doi:10.1016/j.jns.2021.118787","doi":"https://doi.org/10.1016/j.jns.2021.118787","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jns.2021.118787","pdf_url":null,"source":{"id":"https://openalex.org/S169054600","display_name":"Journal of the Neurological Sciences","issn_l":"0022-510X","issn":["0022-510X","1878-5883"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Neurological Sciences","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032850040","display_name":"Renato Mantegazza","orcid":"https://orcid.org/0000-0002-9810-5737","observed_orcids":["https://orcid.org/0000-0002-9810-5737"]},"institutions":[{"id":"https://openalex.org/I4210164485","display_name":"Fondazione IRCCS Istituto Neurologico Carlo Besta","ror":"https://ror.org/05rbx8m02","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210164485"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Renato Mantegazza","raw_affiliation_strings":["Fondazione IRCCS, Istituto Neurologico Carlo Besta, Department of Neuroimmunology and Neuromuscular Diseases, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fondazione IRCCS, Istituto Neurologico Carlo Besta, Department of Neuroimmunology and Neuromuscular Diseases, Milan, Italy","institution_ids":["https://openalex.org/I4210164485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112266809","display_name":"Todd Levine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140312","display_name":"Phoenix Neurological Associates","ror":"https://ror.org/04hk0mm26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140312"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Todd Levine","raw_affiliation_strings":["Phoenix Neurological Associates, Department of Neurology, Phoenix, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Phoenix Neurological Associates, Department of Neurology, Phoenix, United States of America","institution_ids":["https://openalex.org/I4210140312"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088301395","display_name":"Celia Oreja\u2010Guevara","orcid":"https://orcid.org/0000-0002-9221-5716","observed_orcids":["https://orcid.org/0000-0002-9221-5716"]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Celia Oreja-Guevara","raw_affiliation_strings":["Hospital Universitario Cl\u00ednico San Carlos, Department of Neurology, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario Cl\u00ednico San Carlos, Department of Neurology, Madrid, Spain","institution_ids":["https://openalex.org/I2961216182"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088402475","display_name":"Cynthia Carrillo-Infante","orcid":"https://orcid.org/0009-0002-0654-7560","observed_orcids":["https://orcid.org/0009-0002-0654-7560"]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cynthia Carrillo-Infante","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., Medical Safety, Boston, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., Medical Safety, Boston, United States of America","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109320995","display_name":"Eva Laudon Meyer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eva Laudon-Meyer","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., Global Medical Affairs, Boston, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., Global Medical Affairs, Boston, United States of America","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112680645","display_name":"Shulian Shang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shulian Shang","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., Biostatistics, Boston, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., Biostatistics, Boston, United States of America","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088136783","display_name":"Sean Joseph Pittock","orcid":"https://orcid.org/0000-0002-6140-5584","observed_orcids":["https://orcid.org/0000-0002-6140-5584"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Pittock","raw_affiliation_strings":["Mayo Clinic, Center for Multiple Sclerosis and Autoimmune Neurology, Rochester, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Center for Multiple Sclerosis and Autoimmune Neurology, Rochester, United States of America","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036542525","display_name":"James F. Howard","orcid":"https://orcid.org/0000-0002-7136-8617","observed_orcids":["https://orcid.org/0000-0002-7136-8617"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Howard","raw_affiliation_strings":["University of North Carolina, Department of Neurology, Chapel Hill, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Department of Neurology, Chapel Hill, United States of America","institution_ids":["https://openalex.org/I114027177"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3250,"currency":"USD","value_usd":3250},"apc_paid":null,"fwci":0.1671,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.48833309,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"429","issue":null,"first_page":"118787","last_page":"118787"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9286999702453613,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9286999702453613,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.03350000083446503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11735","display_name":"Peripheral Neuropathies and Disorders","score":0.0142000000923872,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eculizumab","display_name":"eculizumab","score":1.0},{"id":"https://openalex.org/keywords/neuromyelitis-optica-spectrum-disorder","display_name":"neuromyelitis optica spectrum disorder","score":0.9549999833106995},{"id":"https://openalex.org/keywords/generalized-myasthenia-gravis","display_name":"generalized myasthenia gravis","score":0.921999990940094},{"id":"https://openalex.org/keywords/infection-rate","display_name":"infection rate","score":0.597000002861023},{"id":"https://openalex.org/keywords/complement-inhibition","display_name":"complement inhibition","score":0.7599999904632568},{"id":"https://openalex.org/keywords/prevent-trial","display_name":"PREVENT trial","score":0.7350000143051147},{"id":"https://openalex.org/keywords/aquaporin-4-antibodies","display_name":"aquaporin-4 antibodies","score":0.7649999856948853},{"id":"https://openalex.org/keywords/acetylcholine-receptor-antibodies","display_name":"acetylcholine receptor antibodies","score":0.8389999866485596},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7260000109672546}],"concepts":[{"id":"https://openalex.org/C2777991916","wikidata":"https://www.wikidata.org/wiki/Q421617","display_name":"Eculizumab","level":4,"score":0.9930248260498047},{"id":"https://openalex.org/C2781137167","wikidata":"https://www.wikidata.org/wiki/Q611458","display_name":"Neuromyelitis optica","level":3,"score":0.8654831647872925},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7326884269714355},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.6406817436218262},{"id":"https://openalex.org/C2778105408","wikidata":"https://www.wikidata.org/wiki/Q8285","display_name":"Myasthenia gravis","level":2,"score":0.5158045291900635},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.48889389634132385},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48873090744018555},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.43845856189727783},{"id":"https://openalex.org/C111684460","wikidata":"https://www.wikidata.org/wiki/Q334848","display_name":"Complement system","level":3,"score":0.42963969707489014},{"id":"https://openalex.org/C2777637130","wikidata":"https://www.wikidata.org/wiki/Q17165460","display_name":"Atypical hemolytic uremic syndrome","level":4,"score":0.4136066734790802},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3285050392150879},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2799934148788452},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08469092845916748},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jns.2021.118787","doi":"https://doi.org/10.1016/j.jns.2021.118787","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jns.2021.118787","pdf_url":null,"source":{"id":"https://openalex.org/S169054600","display_name":"Journal of the Neurological Sciences","issn_l":"0022-510X","issn":["0022-510X","1878-5883"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Neurological Sciences","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309052","display_name":"Alexion Pharmaceuticals","ror":"https://ror.org/031ywxc85"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3155037485","https://openalex.org/W3129249804","https://openalex.org/W3107797672","https://openalex.org/W3083449159","https://openalex.org/W3196179629","https://openalex.org/W3206335561","https://openalex.org/W3086758386","https://openalex.org/W4367303682","https://openalex.org/W4313651321","https://openalex.org/W3196401425"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2021-10-25T00:00:00"}